D&D Pharmatech has initiated Phase 2 clinical trials for its FAP-targeted licensed product based on patented technology. The company is also set to receive milestone payments as the clinical stage progresses.
On July 8, D&D Pharmatech announced that it has been informed by its global partner in radiopharmaceuticals that the first patient has been dosed in the Phase 2 clinical trial of the FAP-targeted PET contrast agent candidate. FAP is a protein that is overexpressed by cancer-associated fibroblasts (CAFs) found in the tumor microenvironment of various solid tumors.
Previously, D&D Pharmatech signed a technology transfer agreement worth $60.4 million (approximately 91.6 billion won) with a global company in the imaging diagnostics sector based in Europe. This agreement pertains to the FAP-targeted PET contrast agent candidate PMI07 and related patent rights held by its wholly-owned subsidiary, Neuraly.
The candidate entering Phase 2 trials is part of a separate pipeline being developed by the partner company for portfolio diversification. According to the agreement, this product falls under the scope of D&D Pharmatech's FAP-targeted patent rights and is eligible for milestone payments upon entering Phase 2.
Separately, PMI07, which D&D Pharmatech has developed and transferred technology for, is currently undergoing Phase 1/2 trials at the University of Texas Southwestern Medical Center. Co-founder Dr. Martin Pomper is involved in this clinical trial, which is studying various solid tumor patients, including those with colorectal, pancreatic, and gastric cancers.
Isulgi, CEO of D&D Pharmatech, stated, "The entry into Phase 2 trials demonstrates that multiple licensed products within our FAP-targeted patent scope, including PMI07, are advancing simultaneously in clinical stages. As several pipelines are progressing smoothly, we expect the commercialization potential of next-generation radiopharmaceuticals encompassing both diagnostics and treatment to expand."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.